Save with Tibsovo from Europe
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe:
Les Laboratoires Servier Industrie
905, route de Saran
45520 Gidy
France
Information about Tibsovo (Ivosidenib)
Tibsovo (ivosidenib) is a medication used in the treatment of certain types of cancers, particularly in patients with acute myeloid leukemia (AML). It is an oral targeted therapy that inhibits mutant isocitrate dehydrogenase-1 (IDH1), a mutation commonly found in some cancers, including AML. By inhibiting the mutant enzyme, Tibsovo helps reduce the growth of cancer cells, leading to improved outcomes for patients with specific genetic mutations.
Product Highlights
- Tibsovo is indicated for the treatment of adult patients with relapsed or refractory AML with an IDH1 mutation, either as monotherapy or in combination with other agents.
- It is also approved for patients with advanced cholangiocarcinoma who have an IDH1 mutation and have received prior treatment.
Key Ingredient
Key Benefits
- Tibsovo is particularly effective for patients whose cancers harbor the IDH1 mutation, including some forms of leukemia and bile duct cancer.
- Tibsovo is an oral medication, which offers convenience compared to injectable therapies.
- As a targeted therapy, ivosidenib focuses on cancer cells with the IDH1 mutation, which can lead to fewer side effects compared to traditional chemotherapy.
- In clinical trials, Tibsovo has shown promise in improving outcomes, such as remission rates and overall survival, in patients with relapsed or refractory AML with the IDH1 mutation.
Direction of Use
- The recommended dosage of Tibsovo is typically 500 mg taken once daily with or without food. The dose may be adjusted based on patient response and tolerability.
- Tibsovo is taken orally as a tablet. It should be taken whole and not broken or chewed.
- If you miss a dose, take it as soon as possible, unless it's almost time for your next dose. Do not take double doses to make up for a missed one.
Safety Concerns
- A potentially life-threatening condition, differentiation syndrome can occur when cancer cells start to differentiate and mature in response to therapy. Symptoms include fever, difficulty breathing, weight gain, and swelling, and it requires immediate medical attention.
- Tibsovo may cause QT interval prolongation, which can lead to serious heart arrhythmias. It is important for patients to have their heart function monitored during treatment.
- Liver function should be monitored during treatment, as Tibsovo can cause liver enzyme elevations or liver damage.
- Patients on Tibsovo may be at increased risk of infections due to its effects on the immune system.
- Tibsovo can be harmful to a developing fetus and should not be used during pregnancy. Effective contraception is recommended during treatment and for some time after treatment.
Avoid Tibsovo (Ivosidenib) If
- You are allergic to ivosidenib or any of the ingredients in the medication.
- You are pregnant or planning to become pregnant, as Tibsovo may harm the fetus.
- You are breastfeeding, as it is not known whether ivosidenib passes into breast milk and may harm the infant.
- You have liver disease or a history of liver problems, as Tibsovo can cause liver toxicity.
- You have a history of heart problems, particularly arrhythmias or QT prolongation, as the drug may worsen these conditions.
- You have a known infection that has not been treated, as patients receiving ivosidenib may have an increased risk of infections.
